Paul Hastings Reps Korean Drug Co. In $126M GSK Deal
The U.K. pharmaceutical giant agreed to buy 9.9 percent of the equity in Dong-A, South Korea's largest drug manufacturer, according to a GlaxoSmithKline filing with the U.S. Securities and Exchange Commission.
GlaxoSmithKline said the collaboration would give the company a chance to further capitalize on the expanding South Korean pharmaceutical market, the 13th-largest in...
To view the full article, register now.